SEC Company Response from Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306) (TNXP) — Jul 15, 2019

Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306)
Date: July 15, 2019 · CIK: 0001430306 · Accession: 0001387131-19-005029

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-232195

Date

July 15, 2019

Author

David W. Boral

Form

CORRESP

Company

Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306)

Letter

Re: Tonix Pharmaceuticals Holding Corp.

July 15, 2019

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E.

Washington, D.C. 20549

Registration Statement on Form S-1 (File No. 333-232195)

Ladies and Gentlemen:

As the underwriter of the proposed offering of Tonix Pharmaceuticals Holding Corp. (the “Company”), we hereby join the Company’s request for acceleration of the above-referenced Registration Statement, requesting effectiveness for 4:30 p.m., Eastern Standard Time, on July 15, 2019, or as soon thereafter as is practicable.

The undersigned advise that they have complied and will continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

Very truly yours,
AEGIS CAPITAL CORP.

Show Raw Text

CORRESP
1
filename1.htm

July
15, 2019

VIA
EDGAR

United
States Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
D.C. 20549

  Re: Tonix
                                         Pharmaceuticals Holding Corp.

Registration
Statement on Form S-1 (File No. 333-232195)

Ladies
and Gentlemen:

As
the underwriter of the proposed offering of Tonix Pharmaceuticals Holding Corp. (the “Company”), we
hereby join the Company’s request for acceleration of the above-referenced Registration Statement, requesting effectiveness
for 4:30 p.m., Eastern Standard Time, on July 15, 2019,
or as soon thereafter as is practicable.

The undersigned advise that they have complied and will continue to comply
with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

    Very truly yours,

    AEGIS CAPITAL CORP.

    By:
    /s/ David W. Boral

    Name:
    David W. Boral

    Title:
    Co- Head of Investment Banking,

    By:
    /s/ Joseph T. Rallo

    Name:
    Joseph T. Rallo

    Title:
    Co-Head of Investment Banking

SecProbe.io